Francis Crick, UCL and AZ identify why treatment fails for NSCLC patients
NSCLC accounts for around 85% of all lung cancer cases, particularly in non-smoking patients
Read More
Tag: EGFR mutations
- European life sciences coalition launched to boost investment ecosystem
- 99mtc‑maraciclatide granted fast track status for ILD imaging
- Bioxytran reports rapid viral clearance in phase 2 trial
- Thx Pharma and Biocodex sign rare disease licensing deal
- AstraZeneca bladder cancer therapy wins NICE backing
